The synthesis of two new isomeric trifunctional dinuclear platinum complexes of formula [¿PtCl(NH(3))(2)¿micro-NH(2)(CH(2))(6)NH(2)-¿PtCl(2)(N H(3))¿](+) (1, 2/c,c and 1,2/t,c) is reported. Their biological activity in selected human tumor cell lines sensitive and resistant to CDDP (cisplatin, cis-[Pt(NH(3))(2)Cl(2)]) is described and compared with the profile for their bifunctional analogues, [¿cis/trans-PtCl(NH(3))(2)¿(2)micro-NH(2)(CH(2))(6)NH(2)](2+ ). The trifunctional dinuclear platinum complexes showed a unique profile of cytotoxicity against human cancer cell lines, with low resistance factors in A2780, CH1, and 41M cell lines. The resistance factor is dependent on the geometry of the Pt coordination spheres - suggesting that these may be associated with DNA-binding modes. Retention of activity against CDDP-resistant cell lines and a different spectrum of activity compared to CDDP and also within different classes of polynuclear platinum complexes suggest that not only are they mechanistically different from mononuclear platinum complexes but also each individual class of polynuclear platinum structure may have its own unique character.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm990536z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel factors of cisplatin resistance in epithelial ovarian tumours.
Adv Med Sci
January 2025
Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovak Republic. Electronic address:
Ovarian tumours are these days one of the biggest oncogynecological problems. In addition to surgery, the treatment of ovarian cancer includes also chemotherapy in which platinum preparations are one of the most used chemotherapeutic drugs. The principle of antineoplastic effects of cisplatin (cis-diamminedichloroplatinum(II), CDDP) is its binding to the DNA and the formation of adducts.
View Article and Find Full Text PDFExploring the Structure-Activity Relationships of Albumin-Targeted Picoplatin-Based Platinum(IV) Prodrugs.
Inorg Chem
January 2025
Faculty of Chemistry, Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria.
Platinum(II) complexes prevail as first-line treatment for many cancers but are associated with serious side effects and resistance development. Picoplatin emerged as a promising alternative to circumvent GSH-induced tumor resistance by introducing a bulky 2-picoline ligand. Although clinical studies were encouraging, picoplatin did not receive approval.
View Article and Find Full Text PDFEZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
Epigenomics
January 2025
Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Background: Aggressive Variant Prostate Cancers (AVPCs) are incurable malignancies. Platinum-based chemotherapies are used for the palliative treatment of AVPC. The Polycomb Repressive Complex 2 (PRC2) promotes prostate cancer progression histone H3 Lysine 27 tri-methylation (H3K27me3).
View Article and Find Full Text PDFSynergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy.
Expert Rev Anticancer Ther
January 2025
Department of Pharmacy, Guru Ghasidas University, Bilaspur, India.
Introduction: The synergistic combination of histone deacetylase inhibitors and platinum-based medicines represents a promising therapeutic strategy to efficacy and overcome drug resistance in cancer therapy, necessitating a comprehensive understanding on their molecular interactions and clinical potential.
Areas Covered: The objective of presented review is to investigate the molecular pathways of platinum medicines and HDAC inhibitors. A comprehensive literature review from 2011 to 2024 was conducted across multiple databases like MEDLINE, PubMed, Google Scholar, Science Direct, Scopus and official websites of ClinicalTrial.
Dual-driven biodegradable nanomotors for enhanced cellular uptake.
J Mater Chem B
January 2025
Bio-Organic Chemistry, Departments of Biomedical Engineering and Chemical Engineering & Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands.
Hybrid nano-sized motors with navigation and self-actuation capabilities have emerged as promising nanocarriers for a wide range of delivery, sensing, and diagnostic applications due to their unique ability to achieve controllable locomotion within a complex biological environment such as tissue. However, most current nanomotors typically operate using a single driving mode, whereas propulsion induced by both external and local stimuli could be more beneficial to achieve efficient motility in a biomedical setting. In this work, we present a hybrid nanomotor by functionalizing biodegradable stomatocytes with platinum nanoparticles (Pt NPs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!